CL2019001685A1 - Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. - Google Patents

Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.

Info

Publication number
CL2019001685A1
CL2019001685A1 CL2019001685A CL2019001685A CL2019001685A1 CL 2019001685 A1 CL2019001685 A1 CL 2019001685A1 CL 2019001685 A CL2019001685 A CL 2019001685A CL 2019001685 A CL2019001685 A CL 2019001685A CL 2019001685 A1 CL2019001685 A1 CL 2019001685A1
Authority
CL
Chile
Prior art keywords
amino acid
methods
diseases
treatment
acid compositions
Prior art date
Application number
CL2019001685A
Other languages
English (en)
Spanish (es)
Inventor
Michael Hamill
Raffi Afeyan
William Comb
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of CL2019001685A1 publication Critical patent/CL2019001685A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2019001685A 2016-12-19 2019-06-19 Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares. CL2019001685A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US201762491776P 2017-04-28 2017-04-28
US201762545358P 2017-08-14 2017-08-14
US201762576321P 2017-10-24 2017-10-24

Publications (1)

Publication Number Publication Date
CL2019001685A1 true CL2019001685A1 (es) 2019-08-30

Family

ID=61025047

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001685A CL2019001685A1 (es) 2016-12-19 2019-06-19 Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.

Country Status (21)

Country Link
US (3) US20180207119A1 (enExample)
EP (1) EP3554493A1 (enExample)
JP (1) JP2020502183A (enExample)
KR (1) KR20190099243A (enExample)
CN (1) CN110267655A (enExample)
AU (1) AU2017379825A1 (enExample)
BR (1) BR112019012476A2 (enExample)
CA (1) CA3046558A1 (enExample)
CL (1) CL2019001685A1 (enExample)
CO (1) CO2019006292A2 (enExample)
CU (1) CU20190057A7 (enExample)
EC (1) ECSP19043725A (enExample)
IL (1) IL267210A (enExample)
JO (1) JOP20190147A1 (enExample)
MA (1) MA50763A (enExample)
MX (1) MX2019007352A (enExample)
PE (1) PE20191206A1 (enExample)
PH (1) PH12019501339A1 (enExample)
TW (1) TWI780096B (enExample)
WO (1) WO2018118957A1 (enExample)
ZA (1) ZA201903581B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
WO2019036442A1 (en) * 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
KR20210023846A (ko) 2018-06-20 2021-03-04 악셀라 헬스 인크. 아미노산 조성물을 제조하는 방법
CN112839712A (zh) * 2018-06-20 2021-05-25 胺细拉健康公司 用于减少或治疗发炎的组合物和方法
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN112752575A (zh) * 2018-09-27 2021-05-04 雀巢产品有限公司 组氨酸、甘氨酸和其它氨基酸用于预防胰岛素抗性和/或糖尿病的用途
BR112021021537A2 (pt) * 2019-06-07 2022-04-19 Nestle Sa Composições e métodos que usam um ou mais aminoácidos indutores de autofagia para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
KR102456270B1 (ko) * 2019-09-24 2022-10-19 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
KR102338447B1 (ko) * 2019-09-24 2021-12-14 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
CN110801007A (zh) * 2019-12-17 2020-02-18 苟春虎 老年肌少症营养肽
US20230089723A1 (en) * 2020-03-06 2023-03-23 Axcella Health Inc. Amino acid compositions and methods for muscle and myotube modulation
US20230390234A1 (en) * 2021-02-26 2023-12-07 Ex Healthcare Inc. Composition inhibiting muscle loss or promoting muscle formation through skin-derived exosomes
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007466A (es) * 2000-02-01 2004-02-26 Muscletech Res And Dev Inc Suplemento alimenticio a base de acido alfa-lipoico para incrementar la masa muscular escas y la fuerza.
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
WO2006009975A2 (en) * 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
JP5545424B2 (ja) * 2005-03-29 2014-07-09 味の素株式会社 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
CN100518815C (zh) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
AU2012299126B2 (en) * 2011-08-19 2016-05-26 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
WO2015061607A1 (en) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Also Published As

Publication number Publication date
CN110267655A (zh) 2019-09-20
JP2020502183A (ja) 2020-01-23
BR112019012476A2 (pt) 2020-04-14
ZA201903581B (en) 2020-12-23
IL267210A (en) 2019-08-29
US20180207119A1 (en) 2018-07-26
CU20190057A7 (es) 2020-02-04
WO2018118957A1 (en) 2018-06-28
AU2017379825A1 (en) 2019-06-13
US20180169047A1 (en) 2018-06-21
TWI780096B (zh) 2022-10-11
CA3046558A1 (en) 2018-06-28
MA50763A (fr) 2019-10-23
PE20191206A1 (es) 2019-09-10
TW201827068A (zh) 2018-08-01
PH12019501339A1 (en) 2019-09-30
MX2019007352A (es) 2019-09-05
JOP20190147A1 (ar) 2019-06-18
CO2019006292A2 (es) 2019-06-28
KR20190099243A (ko) 2019-08-26
ECSP19043725A (es) 2019-07-31
EP3554493A1 (en) 2019-10-23
US20180169046A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
CL2019001685A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.
CL2019001686A1 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas.
ECSP20011578A (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CL2015002641A1 (es) Método para el tratamiento de la enfermedad de parkinson.
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
EA201791154A1 (ru) Лечение болезней и нарушений аналогами кальцитонина
EA201792085A1 (ru) Смешанные дисульфидные конъюгаты тиенопиридиновых соединений и их применение
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.